During a period of upheaval among non-alcoholic steatohepatitis (NASH) R&D competitors, Akero Therapeutics Inc. may be emerging from the middle of the pack with follow-up histology data from its successful Phase IIa study of efruxifermin (EFX/AKR-001) that shows antifibrotic and NASH-resolution effects better than seen in clinical trials for competing drugs.
The expected order in NASH clinical development has overturned in recent weeks, with Genfit SA’s Phase III miss for elafibranor on 12 May followed by Intercept Pharmaceuticals Inc. receiving a complete response letter from the US Food and Drug Administration for obeticholic acid (OCA) on 29 June. (Also see "Intercept’s CRL Just Continues Upheaval In NASH" - Scrip, 29 June, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?